STOCK TITAN

Novartis sees 5% annual net sales growth at constant currency

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Novartis AG expects net sales to grow at a +5% constant-currency CAGR from 2026 to 2031, with its core operating income margin on track to return to 40%+ by 2029.

Peak sales guidance rose for Kesimpta to USD 8 billion from USD 6 billion, Scemblix to USD 5 billion from USD 4 billion, and Leqvio to USD 5 billion from USD 4 billion; Rhapsido/remibrutinib guidance was recently upgraded to USD 8 billion. Novartis lists nine in-market assets with USD 3-10 billion peak-sales potential and expects 35+ potentially submission-enabling readouts through 2031. Its pipeline includes 30+ potential high-value assets, with 10 late-stage assets carrying multi-billion-dollar peak-sales guidance; the company expects these assets to support sustained mid-single-digit sales growth over the long term.

3 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Kesimpta peak sales guidance rose to USD 8 billion from USD 6 billion.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Scemblix peak sales guidance rose to USD 5 billion from USD 4 billion.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Leqvio peak sales guidance rose to USD 5 billion from USD 4 billion.

Negative

  • None.
Net sales CAGR +5% Expected constant-currency CAGR from 2026 to 2031
Core operating income margin 40%+ On track to return to this level by 2029
Kesimpta peak sales guidance USD 8 billion Raised from USD 6 billion
Scemblix peak sales guidance USD 5 billion Raised from USD 4 billion
Leqvio peak sales guidance USD 5 billion Raised from USD 4 billion
Rhapsido/remibrutinib peak sales guidance USD 8 billion Across chronic spontaneous urticaria, chronic inducible urticaria and relapsing multiple sclerosis
In-market assets' peak sales potential USD 3-10 billion Nine assets
Potentially submission-enabling readouts 35+ Expected through 2031
CAGR financial
"a +5% cc CAGR from 2026 to 2031"
Compound Annual Growth Rate (CAGR) measures the average yearly growth of an investment, revenue, or other metric over a multi-year period as if it had grown at a steady rate each year. Think of it like the constant speed that would take you from the starting value to the ending value over the same time—useful because it smooths out ups and downs and lets investors compare different assets or performance periods on an even footing.
constant currencies financial
"Constant currencies (cc) and core results are non-IFRS measures"
Constant currencies is a way companies report sales and profit changes as if exchange rates had not moved, isolating underlying business performance from currency swings. For investors it matters because it shows whether growth comes from actual demand or just favorable exchange-rate moves—think of it like comparing two stores’ receipts after converting prices to the same stable money to see who actually sold more, not who benefitted from changing rates.
core operating income margin financial
"core operating income margin on track to return to 40%+ by 2029"
submission-enabling readouts medical
"35+ potentially submission-enabling readouts through 2031"
siRNA medical
"QCZ484, an siRNA with twice-yearly dosing for hypertension"
Small interfering RNA (siRNA) is a short strand of genetic material that binds to and destroys the messenger RNA that carries instructions for making a specific protein, effectively switching that gene off. Investors care because siRNA is a platform for precise medicines: successful trials or approvals can create high-value drugs, while delivery challenges, manufacturing complexity, patent positions and regulatory risk can sharply affect a biotech company's prospects.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is NVS's sales growth outlook through 2031?

Novartis expects net sales to grow at a +5% constant-currency CAGR from 2026 to 2031; its core operating income margin is on track to return to 40%+ by 2029.

Which NVS brands had higher peak sales guidance?

Peak sales guidance rose for Kesimpta to USD 8 billion, Scemblix to USD 5 billion, and Leqvio to USD 5 billion. The prior guidance levels were USD 6 billion, USD 4 billion, and USD 4 billion, respectively. Rhapsido/remibrutinib was recently upgraded to USD 8 billion.

How many NVS pipeline assets are in later development stages?

Novartis describes 30+ potential high-value assets across four core therapeutic areas and three advanced technology platforms: 20+ are in registration, Phase III or Phase II, and 10+ are in or entering Phase I. Ten late-stage assets have multi-billion-dollar peak sales guidance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 or 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Report on Form 6-K dated November 19, 2026

(Commission File No. 1-15024)

 

____________________

 

Novartis AG

(Name of Registrant)

 

Lichtstrasse 35

4056 Basel

Switzerland

(Address of Principal Executive Offices)

 

____________________

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F: ☒   Form 40-F: ☐

 

 

 

 

 

 

Novartis International AG

CH-4002 Basel

Switzerland

 

https://www.novartis.com

https://x.com/novartisnews

 

 

PRESS RELEASE

Novartis projects +5% cc1 sales CAGR through 2031 and sustained mid-single-digit growth over the long term

Ad hoc announcement pursuant to Art. 53 LR

  • Net sales expected to grow at a +5% cc1 CAGR from 2026 to 2031; core operating income margin1 on track to return to 40%+ by 2029
     
  • Peak sales guidance upgraded for Kesimpta, Scemblix and Leqvio, building on the recent upgrade for Rhapsido/remibrutinib; nine in-market assets now with USD 3-10 billion peak sales potential
     
  • 35+ potentially submission-enabling readouts through 2031 and 30+ potential high-value pipeline assets, including 10 in late-stage development with multi-billion-dollar peak sales guidance, expected to support sustained mid-single-digit growth long term

Basel, November 19, 2026 – Novartis today rolled forward its mid-term guidance to 2026-2031, with net sales expected to grow at a +5% cc1 CAGR, and core operating income margin1 on track to return to 40%+ by 2029. The updated outlook will be featured at the Meet Novartis Management event in London and reflects continued momentum from in-market growth drivers as well as upcoming launches.

Higher peak sales guidance for three key brands reinforces confidence in the company’s mid-term outlook:

  • Kesimpta raised from USD 6 billion to USD 8 billion
  • Scemblix raised from USD 4 billion to USD 5 billion
  • Leqvio raised from USD 4 billion to USD 5 billion

This follows the recent upgrade of Rhapsido/remibrutinib peak sales guidance to USD 8 billion across chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and relapsing multiple sclerosis (RMS), with additional multi-billion-dollar potential across all other indications.

Novartis now has nine de-risked, in-market assets with peak sales potential of USD 3-10 billion: Kisqali, Rhapsido, Cosentyx, Kesimpta, Pluvicto, Scemblix, Leqvio, the Zolgensma Group (Zolgensma and Itvisma) and Fabhalta.

Beyond its in-market portfolio, Novartis expects 35+ potentially submission-enabling readouts through 2031. The pipeline includes 30+ potential high-value assets across four core therapeutic areas and three advanced technology platforms: 20+ in registration, Phase III or Phase II, and 10+ currently in or entering Phase I. Ten of the assets in late-stage development have multi-billion-dollar peak sales guidance. Together, these are expected to support sustained mid-single-digit sales growth over the long term.

 

 

Select pipeline assets being highlighted at the event include:

  • In cardiovascular-renal-metabolic: abelacimab, a Factor XI/XIa inhibitor for stroke prevention in atrial fibrillation; QCZ484, an siRNA with twice-yearly dosing for hypertension; and farabursen, a first-in-class miR-17 inhibitor for autosomal dominant polycystic kidney disease (ADPKD)
  • In immunology: GHZ339, a potential first IL-13/IL-18 bispecific for atopic dermatitis; Rhapsido in food allergy; ianalumab in systemic lupus erythematosus; and GIA632, an IL-15 inhibitor, for vitiligo and lichen planus
  • In neuroscience: del-brax for facioscapulohumeral muscular dystrophy (FSHD); del-zota for Duchenne muscular dystrophy amenable to exon 44 skipping (DMD44); and votoplam for Huntington’s disease
  • In oncology: pelabresib in myelofibrosis, 225Ac-PSMA-617 (AAA817) in prostate cancer, and our breast cancer portfolio spanning CDK inhibitors, pan-mutant PI3Kα inhibitor, RLT and ADCs

“As a pure-play innovative medicines company, Novartis has a strong track record of sales growth and core margin expansion, and in 2026 we expect to grow through the largest loss-of-exclusivity impact in our history,” said Vas Narasimhan, CEO of Novartis. “The strength of our in-market portfolio is reflected in higher peak sales guidance for Rhapsido, Kesimpta, Scemblix and Leqvio, which together with our other priority brands underpin our expectation of a +5% cc1 sales CAGR through 2031. Alongside our late-stage programs advancing through Phase III, our full Phase I and II pipeline gives us further confidence that we can sustain mid-single-digit growth over the longer term.”

During the event today, investors and analysts will hear a strategy and performance update from Vas Narasimhan, including how Novartis is scaling AI across research, development, manufacturing and commercial operations, and have the opportunity to engage with senior leaders across therapeutic areas in an open Q&A format. A live webcast of the event will be available on our website at https://www.novartis.com/investors/event-calendar, along with a copy of the CEO presentation. A replay will be available once the event has concluded.

Disclaimer

This communication contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “expected,” “potential,” “guidance,” “on track,” “outlook,” “can,” “will,” “growth,” “expectations,” “advancing,” “confidence,” “continued,” “ongoing,” “launch,” “priority,” “momentum,” “pipeline,” “progress,” “emerging,” or similar expressions, or by express or implied discussions regarding: potential new products, potential new indications for existing products, potential product launches or potential future revenues from any such products; or results of ongoing clinical trials; potential future, pending or announced transactions; potential future sales or earnings; strategy, plans, expectations or intentions, including discussions regarding our continued investment into new R&D capabilities and manufacturing; our capital structure. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this communication will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. Neither can there be any guarantee that the expected benefits or synergies from the transactions described in this communication will be achieved in the expected timeframe, or at all. In particular, our expectations could be affected by, among other things, uncertainties concerning: global healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; the success of key products, commercial priorities and strategy; the research and development of new products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products; our ability to realize the strategic benefits, operational efficiencies or opportunities expected from our external business opportunities; the development or adoption of new technologies, including artificial intelligence, and new business models; the implementation of our new IT projects and systems; potential significant breaches of information security or disruptions of our information technology systems; actual or potential legal proceedings, including regulatory actions or delays or government regulation related to the products and pipeline products described in this communication; safety, quality, data integrity, or manufacturing issues; our performance on and ability to comply with environmental, social and governance measures and requirements; major macroeconomic and geo- and socio-political developments, including the impact of any potential tariffs on our products or the impact of war in certain parts of the world; future global exchange rates; future demand for our products; and other risks and factors referred to in Novartis AG’s most recently filed Form 20-F and in subsequent reports filed with, or furnished to, the US Securities and Exchange Commission. Novartis is providing the information in this communication as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

 

 

All product names appearing are trademarks owned by or licensed to Novartis.

This communication includes non-IFRS financial measures, including constant currencies (cc) and core results. An explanation of non-IFRS measures can be found on page 45 of the Novartis Third Quarter and Nine Months 2026 Condensed Interim Financial Report.

About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.

Reimagine medicine with us: Visit us at www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

References
1.    Constant currencies (cc) and core results are non-IFRS measures. An explanation of non-IFRS measures can be found on page 45 of the Novartis Third Quarter and Nine Months 2026 Condensed Interim Financial Report.

# # #

Novartis Media Relations
E-mail: media.relations@novartis.com
    
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

 

 

 

 

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Novartis AG  
       
       
Date: November 19, 2026 By: /s/ PAUL PENEPENT  
  Name:  Paul Penepent  
  Title: Head of Financial Reporting and Accounting

 

 

 

 

 

 

 

Keep reading